Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 17, 2025 04:00 ET | Source: Microbiotica

Microbiotica Announces Completion of Recruitment in its International Phase 1b Trial (MELODY-1) of MB097, a Precision Microbiome Co-Therapy in Advanced Melanoma

CAMBRIDGE, United Kingdom, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic...
August 04, 2025 04:00 ET | Source: Microbiotica

Microbiotica Announces Completion of Recruitment in its Phase 1b Trial (COMPOSER-1) of MB310, a Precision Microbiome Medicine, in Ulcerative Colitis Patients

CAMBRIDGE, United Kingdom, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic...
May 06, 2025 04:00 ET | Source: Microbiotica

Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrier

CAMBRIDGE, United Kingdom, May 06, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma Company developing a pipeline of oral precision microbiome medicines called live biotherapeutic...
April 29, 2025 04:00 ET | Source: Microbiotica

Microbiotica reveals novel mechanisms showing how the microbiome can improve immunotherapy response based on MB097, a clinical-stage drug candidate being evaluated in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma

CAMBRIDGE, United Kingdom, April 29, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic...
February 26, 2025 04:00 ET | Source: Microbiotica

Microbiotica presented new data on the mechanism of action of MB097, a clinical-stage drug candidate being developed as a co-therapy in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma

CAMBRIDGE, United Kingdom, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic...
February 21, 2025 07:00 ET | Source: Microbiotica

Microbiotica unveils data on the mechanism of action of MB310, a clinical-stage drug candidate in development for the treatment of ulcerative colitis

CAMBRIDGE, United Kingdom, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic...
November 13, 2024 04:00 ET | Source: Microbiotica

Microbiotica Announces First Patient Dosed in its Phase 1b Trial (COMPOSER-1) of MB310, a Precision Microbiome Medicine, in Ulcerative Colitis Patients

CAMBRIDGE, United Kingdom, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic...
October 07, 2024 04:00 ET | Source: Microbiotica

Microbiotica Announces First Patient Dosed in its International Phase 1b Trial, MELODY-1 of MB097 Precision Microbiome Co-Therapy in Advanced Melanoma

CAMBRIDGE, United Kingdom, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic...
August 27, 2024 04:00 ET | Source: Microbiotica

Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory Approvals in EU and UK for Phase 1b Studies

CAMBRIDGE, United Kingdom, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Microbiotica, a biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products...
July 09, 2024 04:00 ET | Source: Microbiotica

Microbiotica to Present Positive Update on Manufacturing Progress of its Live Biotherapeutic Products for Forthcoming Melanoma and Ulcerative Colitis Clinical Studies

Presentation in Boston at 9th Microbiome Movement Drug Development Summit, 10-12 July 2024 CAMBRIDGE, UK , July 09, 2024 (GLOBE NEWSWIRE) -- Microbiotica, a biopharma company developing a pipeline...